Lu AG09222

DRUG6 trials

Sponsors

H. Lundbeck A/S

Conditions

Allergic RhinitisHealthyMigraine

Phase 1

A Single Dose Study of Lu AG09222 in a Headache Model With Healthy Subjects

CompletedNCT04976309

H. Lundbeck A/SHealthy

Start: 2021-07-15End: 2021-12-10Updated: 2022-01-19

A Trial to Learn More About Repeated Monthly Injections of Lu AG09222 in Participants With Allergies to Grass Pollen

CompletedNCT05126316

H. Lundbeck A/SAllergic Rhinitis

Start: 2021-11-01End: 2022-08-25Updated: 2022-10-27

A Study Investigating the Movement of Lu AG09222 Into, Through, and Out of the Body of Healthy Caucasian, Chinese, and Japanese Participants

CompletedNCT05304910

H. Lundbeck A/SMigraine

Start: 2022-03-18End: 2022-10-30Updated: 2022-11-10

A Trial Investigating Lu AG09222 With Ubrogepant in Participants With Migraine

CompletedNCT06578585

H. Lundbeck A/SMigraine

Start: 2024-09-13End: 2025-07-11Updated: 2025-10-14

Phase 2

A Study With Lu AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments

CompletedNCT05133323

H. Lundbeck A/SMigraine

Start: 2021-11-11End: 2023-03-16Updated: 2024-03-13

A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments

CompletedNCT06323928

H. Lundbeck A/SMigraine

Start: 2024-04-01End: 2026-03-16Updated: 2026-06-12

Related Papers

A Monoclonal Antibody to PACAP for Migraine Prevention

New England Journal of Medicine2024-09-0464 citations

The effect of Lu AG09222 on PACAP38- and VIP-induced vasodilation, heart rate increase, and headache in healthy subjects: an interventional, randomized, double-blind, parallel-group, placebo-controlled study.

2023-05-2531 citations